Rigel Pharmaceuticals RIGL - 옵션 체인 | ADVFN

다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

홈
인베스팅
주식
미국
NASDAQ
Rigel Pharmaceuticals Inc (RIGL)
Rigel Pharmaceuticals Inc (RIGL) 옵션

Rigel Pharmaceuticals Inc (RIGL)

19.28

0.22

(1.15%)

종가: 26 4월 5:00AM

19.28

0.00

( 0.00% )

시간외 거래: 5:30AM

RIGL 실시간 옵션 플로우

콜

행사 가격	매수가	매도가	최근 가격	중간 가격	가격 변동	가격 변동 %	거래량	미결제 약정	최근 거래
10.00	7.20	11.00	0.00	9.10	0.00	0.00 %	0	0	-
11.00	6.00	10.20	0.00	8.10	0.00	0.00 %	0	0	-
12.00	5.10	8.50	0.00	6.80	0.00	0.00 %	0	0	-
13.00	4.00	8.70	0.00	6.35	0.00	0.00 %	0	0	-
14.00	3.30	7.60	0.00	5.45	0.00	0.00 %	0	0	-
15.00	2.35	6.60	0.00	4.475	0.00	0.00 %	0	0	-
16.00	1.65	6.00	2.98	3.825	0.00	0.00 %	0	2	-
17.00	0.75	4.90	1.65	2.825	0.00	0.00 %	0	7	-
18.00	0.30	2.60	1.45	1.45	0.00	0.00 %	0	7	-
19.00	1.15	2.20	0.80	1.675	0.00	0.00 %	0	6	-
20.00	0.85	1.50	1.20	1.175	0.33	37.93 %	5	31	22:30:01
21.00	0.45	1.55	0.00	1.00	0.00	0.00 %	0	0	-
22.00	0.45	0.85	0.05	0.65	0.00	0.00 %	0	19	-
23.00	0.05	1.75	0.00	0.90	0.00	0.00 %	0	0	-
24.00	0.00	1.05	0.96	0.96	0.00	0.00 %	0	2	-
25.00	0.00	1.75	1.10	1.10	0.00	0.00 %	0	1	-
26.00	0.00	0.75	0.38	0.38	0.00	0.00 %	0	7	-
27.00	0.00	1.25	1.02	1.02	0.00	0.00 %	0	1	-
28.00	0.00	1.25	0.00	0.00	0.00	0.00 %	0	0	-

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

풋

행사 가격	매수가	매도가	최근 가격	중간 가격	가격 변동	가격 변동 %	거래량	미결제 약정	최근 거래
10.00	0.00	1.50	0.87	0.87	0.00	0.00 %	0	1	-
11.00	0.00	0.90	0.00	0.00	0.00	0.00 %	0	0	-
12.00	0.00	1.25	0.00	0.00	0.00	0.00 %	0	0	-
13.00	0.00	0.75	0.00	0.00	0.00	0.00 %	0	0	-
14.00	0.00	1.25	0.00	0.00	0.00	0.00 %	0	0	-
15.00	0.05	1.15	0.75	0.60	0.00	0.00 %	0	5	-
16.00	0.20	0.85	0.40	0.525	-0.25	-38.46 %	1	23	04:54:08
17.00	0.45	1.30	0.00	0.875	0.00	0.00 %	0	0	-
18.00	0.65	2.10	0.00	1.375	0.00	0.00 %	0	0	-
19.00	1.20	1.75	3.24	1.475	0.00	0.00 %	0	20	-
20.00	1.30	2.60	2.10	1.95	0.00	0.00 %	10	0	00:15:42
21.00	1.15	4.40	0.00	2.775	0.00	0.00 %	0	0	-
22.00	1.55	5.60	0.00	3.575	0.00	0.00 %	0	0	-
23.00	2.20	6.50	0.00	4.35	0.00	0.00 %	0	0	-
24.00	3.60	7.50	0.00	5.55	0.00	0.00 %	0	0	-
25.00	3.90	8.20	0.00	6.05	0.00	0.00 %	0	0	-
26.00	4.80	9.40	0.00	7.10	0.00	0.00 %	0	0	-
27.00	6.00	10.20	0.00	8.10	0.00	0.00 %	0	0	-
28.00	6.90	11.00	0.00	8.95	0.00	0.00 %	0	0	-

가장 활성
% 상승자
% 패자

기호	가격	볼륨
MOLNMolecular Partners AG	US$ 5.02 (19.55%)	238.15k
MHUAMeihua International Medical Technologies Company Ltd	US$ 0.33 (11.56%)	492.44k
CASKHeritage Distilling Holding Company Inc	US$ 0.643632 (10.36%)	1.5k
BULLWebull Corporation	US$ 18.9401 (9.67%)	873.32k
BSGMBioSig Technologies Inc	US$ 0.9999 (8.68%)	105.9k
JZXNJiuzi Holdings Inc	US$ 2.35 (-20.88%)	232.23k
ULYUrgent ly Inc	US$ 6.41 (-16.10%)	69.61k
RETOReTo Eco Solutions Inc	US$ 3.55 (-8.51%)	13.47k
CHSNChanson International Holding	US$ 0.2847 (-6.90%)	10.14k
MDGLMadrigal Pharmaceuticals Inc	US$ 305.0001 (-6.67%)	3.15k
WWWW International Inc	US$ 0.3958 (0.05%)	21.96M
DMNDamon Inc	US$ 0.0035 (0.00%)	5.15M
OMEXOdyssey Marine Exploration Inc	US$ 1.47 (-2.65%)	3.77M
RTCBaijiayun Group Ltd	US$ 0.317154 (-2.53%)	3.48M
GNLNGreenlane Holdings Inc	US$ 0.0124 (0.00%)	3.14M

dcaf7

dcaf7 1 년 전

Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.

Monksdream

Monksdream 1 년 전

Monksdream

Monksdream 1 년 전

dcaf7

dcaf7 1 년 전

Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/

dcaf7

dcaf7 1 년 전

Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.

dcaf7

dcaf7 1 년 전

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023

bme

Rigl should be VTGN (Today) one day.

bme

Yeah. Should be good Q.

TucsonPhil

TucsonPhil 2 년 전

Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.

bme

Better be good.

bme

The Night Stalker

The Night Stalker 2 년 전

The Night Stalker

The Night Stalker 2 년 전

The Night Stalker

The Night Stalker 2 년 전

bme

What a shoot! Amazing.

bme

The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?

The Night Stalker

The Night Stalker 2 년 전

The Night Stalker

The Night Stalker 2 년 전

The Night Stalker

The Night Stalker 2 년 전

The Night Stalker

The Night Stalker 2 년 전

bme

Nice spike AH today.

bme

Higher low higher low.... next leg is North.

The Night Stalker

The Night Stalker 2 년 전

https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100

The Night Stalker

The Night Stalker 2 년 전

https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100

bme

acting wild atm, but still healthy.

The Night Stalker

The Night Stalker 2 년 전

bme

Nice & Healthy.

The Night Stalker

The Night Stalker 2 년 전

The Night Stalker

The Night Stalker 2 년 전

The Night Stalker

The Night Stalker 2 년 전

The Night Stalker

The Night Stalker 2 년 전

The Night Stalker

The Night Stalker 2 년 전

bme

The Night Stalker

The Night Stalker 2 년 전

The Night Stalker

The Night Stalker 2 년 전

bme

Expect Q4 filing this week?

bme

Be seeing that. Lot of 1.95 transactions so far

TucsonPhil

TucsonPhil 2 년 전

Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.

bme

SP should be a lot higher since the Q4 revenue is more than double from last year...

Welldoctor

Welldoctor 2 년 전

Apparently insider buying reported on ST. Take it for what it’s worth.

Welldoctor

Welldoctor 2 년 전

bme

Looks like it will poke thru & bye bye 1 today.

doesitreallymatter

doesitreallymatter 2 년 전

Just like ABQQ. Right?

subslover

subslover 2 년 전

You are 1/2 way there!!!!

KngmAz

KngmAz 2 년 전

Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!

KngmAz

KngmAz 2 년 전

This is a $10.00 per share stock in the very near future - EASILY!!

Alaska40

Alaska40 2 년 전

I just bought in. Seems like a good run could come in the near future.

subslover

subslover 2 년 전

Consolidating nicely on Continuation from last week!

bcapps66

bcapps66 2 년 전

THEMASTERS_SON

THEMASTERS_SON 2 년 전

GIVE ME MY $2DOLLAS…YA BUM

Rigel Pharmaceuticals

Direxion Daily S&P Biote...

Apellis Pharmaceuticals

Direxion Daily Regional ...

Direxion Daily Csi China...

Invesco S&P MidCap 400 R...

SPDR Portfolio S&P 1500 ...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관